Clinical Performance Study for PD-L1 IHC 22C3 pharmDx on Non-Squamous Non-Small Cell Lung Cancer Specimens.

Clinical Performance Study for PD-L1 IHC 22C3 pharmDx on Non-Squamous Non-Small Cell Lung Cancer Specimens. - Not applicable

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON53353

Enrollment

Registered

2023-07-28

Start date

2023-06-30

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

The IVD test results from PD-L1 IHC 22C3 pharmDx will be used for patients selection using PD-L1 expression level TPS

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Subjects included in the performance study will be those enrolled in the TROPION-Lung07 clinical trial.

Exclusion criteria

Exclusion criteria: Subjects excluded from the performance study will be those ineligible for the TROPION-Lung07 clinical trial.

Design outcomes

Primary

Measure	Time frame
The objective of using PD-L1 IHC 22C3 pharmDx in the clinical trial is to use PD-L1 expression level for patient selection at TPS	—

Countries

Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Italy, Japan, Mexico, Netherlands, South Korea, Taiwan, Thailand, Turkey, United Kingdom

Contacts

Public ContactF.G. Plas

Propharmagroup

TBEU-clinicaltrials@daiichi-sankyo.eu+498978080

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Apr 17, 2026